Management of bipolar I depression: Clinical utility of lurasidone

Therapeutics and Clinical Risk Management

Volumn 11, Issue , 2015, Pages 75-81

  Findlay, Lillian Jan ^a   El Mallakh, Peggy ^a   El Mallakh, Rif S ^b  

^a UNIVERSITY OF KENTUCKY COLLEGE OF NURSING   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Adjunctive therapy; Bipolar depression; Bipolar disorder; Lurasidone

Indexed keywords

ASENAPINE; CHOLESTEROL; DOPAMINE; GLUCOSE; ILOPERIDONE; LITHIUM SALT; LURASIDONE; PALIPERIDONE; PLACEBO; PROLACTIN; VALPROIC ACID;

AKATHISIA; ANTIDEPRESSANT ACTIVITY; BIPOLAR I DISORDER; BODY WEIGHT DISORDER; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSOMNIA; LOW DRUG DOSE; MAJOR DEPRESSION; MONOTHERAPY; NAUSEA; NONHUMAN; PARKINSONISM; PROLACTIN BLOOD LEVEL; REVIEW; SCHIZOPHRENIA; SEDATION; SOMNOLENCE; TREATMENT INDICATION; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT; VOMITING; XEROSTOMIA;

EID: 84930480288     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S57695     Document Type: Review

References (62)

1. Altshuler LL, Kupka RW, Hellemann G, et al. Gender and depressive symptoms in 711 patients with bipolar disorder evaluated prospectively in the Stanley Foundation bipolar treatment outcome network. Am J Psychiatry. 2010;167(6):708–715.
2. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530–537.
3. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60(3):261–269.
4. Post RM, Leverich GS, Nolen WA, et al. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network. Bipolar Disord. 2003;5(6): 396–406.
5. Altshuler LL, Post RM, Black DO, et al. Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. J Clin Psychiatry. 2006;67(10):1551–1560.
6. Goldstein BI, Herrmann N, Shulman KI. Comorbidity in bipolar disorder among the elderly: results from an epidemiological community sample. Am J Psychiatry. 2006;163(2):319–321.
7. McElroy SL, Keck PE Jr. Metabolic syndrome in bipolar disorder: a review with a focus on bipolar depression. J Clin Psychiatry. 2014;75(1): 46–61.
8. Rezaeitalab F, Moharrari F, Saberi S, Asadpour H, Rezaeetalab F. The correlation of anxiety and depression with obstructive sleep apnea syndrome. J Res Med Sci. 2014;19(3):205–210.
9. Saunamäki T, Jehkonen M. Depression and anxiety in obstructive sleep apnea syndrome: a review. Acta Neurol Scand. 2007;116(5):277–288.
10. Post RM, Altshuler LL, Leverich GS, et al. More medical comorbidities in patients with bipolar disorder from the United States than from the Netherlands and Germany. J Nerv Ment Dis. 2014;202(4):265–270.
11. Sierra P, Cámara R, Tobella H, Livianos L. What is the real significance and management of major thyroid disorders in bipolar patients? Rev Psiquiatr Salud Ment. 2014;7(2):88–95.
12. Williams MD, Shah ND, Wagie AE, Wood DL, Frye MA. Direct costs of bipolar disorder versus other chronic conditions: an employer-based health plan analysis. Psychiatr Serv. 2011;62(9):1073–1078.
13. Cascade EF, Reites J, Kalali AH, Ghaemi N. Antidepressants in bipolar disorder. Psychiatry (Edgmont). 2007;4(3):56–58.
14. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society of Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;70(11):1249–1262.
15. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161(9):1537–1547.
16. El-Mallakh RS, Karippot A. Chronic depression in bipolar disorder. Am J Psychiatry. 2006;163(8):1137–1341.
17. Amsterdam J. Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode. J Clin Psychopharmacol. 1998;18(5): 414–417.
18. Amsterdam JD, Garcia-España F, Fawcett J, et al. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol. 1998;18(6):435–440.
19. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079–1088.
20. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebocontrolled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158(6):906–912.
21. El-Mallakh RS. Adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;357(6):615.
22. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356(17):1711–1722.
23. Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry. 1987;144(11):1403–1411.
24. El-Mallakh RS, Ghaemi SN, Sagduyu K, et al. Antidepressant-Associated Chronic Irritable Dysphoria (ACID) in STEP-BD Patients. J Affect Disord. 2008;111(2–3):372–377.
25. Ghaemi SN, Ostacher MM, El-Mallakh RS, et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry. 2010;71(4):372–380.
26. Schroeder E, Gao Y, Roberts RJ, El-Mallakh RS. Recognition and management of bipolar depression. J Clin Outcomes Manag. 2011; 18(11):515–525.
27. Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valenti M, Vieta E. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol. 2010;13(1):5–14.
28. DeFruyt J, Deshepper E, Audenaert K, et al. Second generation antipsychotic in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacology. 2012;26(5):603–617.
29. Nakamura M, Ogasa MS, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829–836.
30. Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47(5):670–677.
31. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebocontrolled study. Am J Psychiatry. 2014;171(2):160–168.
32. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: A randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):169–177.
33. Preskorn S, Ereshefsky L, Chiu Y-Y, Poola N, Loebel A. Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies. Hum Psychopharmacol. 2013; 28(5):495–505.
34. Hamelin BA, Allard S, Laplante L, et al. The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy. 1998;18(1):9–15.
35. Gandelman K, Alderman JA, Glue P, et al. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. J Clin Psychiatry. 2009;70(1):58–62.
36. Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs. 2009;18(11): 1715–1726.
37. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334(1):171–181.
38. Uhida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011; 31(4):497–502.
39. Wong DF, Kuwabara H, Brašić JR, et al. Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacology (Berl). 2013;229(2):245–252.
40. Potkin SG, Keator DB, Kesler-West ML, et al. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia and schizoaffective disorder. CNS Spectr. 2014;19(2):176–181
41. Hedlund PB, Huitron-Resendiz S, Henriksen SJ, Sutcliffe JG. 5-HT7 receptor inhibition and inactivation induce antidepressant like behavior and sleep pattern. Biol Psychiatry. 2005;58(10):831–837.
42. Wesolowska A, Nikiforuk A, Stachowicz K, Tatarczynska E. Effect of the selective-5HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology. 2006;51(3):578–586.
43. Bonaventure P, Dugovic C, Kramer M, et al. Translational evaluation of JNJ-18038683, a 5-HT7 receptor antagonist, on REM sleep and in major depressive disorder. J Pharmacol Exp Ther. 2012;342(2):429–440.
44. Bonaventure P, Kelly L, Aluisio L, et al. Selective blockade of 5-hydroxytryptamine 5HT7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. J Pharmacol Exp Ther. 2007;321(2): 690–698.
45. Cates LN, Roberts AJ, Huitron-Resendiz S, Hedlund PB. Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtype. Neuropharmacology. 2013;70:211–217.
46. Huang M, Horiguchi M, Felix AR, Meltzer HY. 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. Neuroreport. 2012;23(7):436–440.
47. Huang M, Panos JJ, Kwon S, Oyamada Y, Rajagopal L, Meltzer HY. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin 5HT2A and DA D2 antagonism and 5-HT1A partial agonism. J Neurochem. 2014; 128(6):938–949.
48. Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol. 2011;11(1): 59–67.
49. Horisawa T, Ishibashi T, Nishikawa H, et al. The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. Behav Brain Res. 2011;220(1):83–90.
50. Horisawa T, Nishikawa H, Toma S, et al. The role of 5-HT7 receptor antagonism in the amelioration of MK-801-induced learning and memory deficits by the novel atypical antipsychotic drug lurasidone. Behav Brain Res. 2013;244:66–69.
51. Yuen EY, Li X, Wei J, Horiguchi M, Meltzer HY, Yan Z. The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptormediated synaptic responses. Mol Pharmacol. 2012;81(2):113–119.
52. Fumagalli F, Calabrese F, Luoni A, Bolis F, Racagni G, Riva MA. Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress. Int J Neuropscyhophramcol. 2012;15(2):235–246.
53. Luoni A, Berry A, Calabrese F, et al. Delayed BDNF alterations in the prefrontal cortex of rats exposed to prenatal stress: preventive effect of lurasidone treatment during adolescence. Eur Neuropsychopharmacol. 2014;24(6):986–995.
54. Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev Neurobiol. 2010;70(5):289–297.
55. Sunovion Pharmaceuticals Inc. The US Food and Drug Administration approved Latuda® (lurasidone HCl) for the treatment of adult patients with depressive episodes associated with bipolar I disorder (bipolar depression), both as monotherapy and as an adjunct to lithium or valproate; June 28, 2013. Available from: http://www.sunovion.com/news/latuda-press-room.html. Accessed July 4, 2014.
56. Latuda® (lurasidone HCI tablets) [prescribing information]. Sunovion Pharmaceuticals Inc; 2013.
57. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placeboand-olanzapine-controlled study. Am J Psychiatry. 2011;168(9): 957–967.
58. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011;65(2):189–210.
59. Citrome L, Ketter TA, Cucchiaro J, Loebel A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2014;155:20–27.
60. De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone, and paliperidone in the treatment of schizophrenia and bipolar disorder. CNS Drugs. 2012;26(9):733–759.
61. Howland RH. Update on newer antipsychotic drugs. J Psychosoc Nurs Ment Health Serv. 2011;49(4):13–15.
62. Rado J, Janicak PG. Pharmacological and clinical profile of recently approved second-generation antipsychotics. Drugs Aging. 2012; 29(10):783–791.